IBA Reports Full Year Results for 2018

Thursday, March 21, 2019 - 09:00
Industrial Solutions
Louvain-La-Neuve, Belgium, March 21, 2019 - IBA (Ion Beam Applications SA, EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces its
consolidated annual results for the 2018 financial year.
 
On July 20, 2018, IBA announced that it had decided to explore new strategic alternatives for IBA Dosimetry which could include a sale, merger, initial public offering, or retention of the business. Following the announcement, IBA initiated a disposal process and determined that all criteria of IFRS 5 were met in order to present the assets and liabilities of IBA Dosimetry as assets held-for-sale. As IBA Dosimetry is also a separate operating segment, it also meets the criteria of discontinued operations. Consequently the results of this activity are presented on a separate line in the income statement as “Profit/(loss) from discontinued operations” in 2018 and in the comparative numbers
for 2017. Active discussions are currently ongoing on the sale of this division and the Company expects to inform the market of the outcome of these discussions in Q2 2019.
Back to news